SGSM3: A Potential Drug Target and Biomarker for the Treatment of SGSM-Related Diseases

Target Name: SGSM3

NCBI ID: G27352

SGSM3

SGSM3: A Potential Drug Target and Biomarker for the Treatment of SGSM-Related Diseases

Introduction

Sickle cell disease (SCD) is a genetic disorder that affects the structure of hemoglobin in red blood cells, leading to a wide range of health problems, including chronic pain, organ damage, and life-threatening complications. One of the main genetic mutations associated with SCD is the sickle cell membrane defect (SCDM), which results in the improper functioning of the sickle cell vesicles. SGSM3, a protein that is expressed in the sickle cells, has been identified as a potential drug target and biomarker for the treatment of SCD and other SGSM-related diseases.

SGSM3: Structure and Function

SGSM3 is a 14-kDa protein that is expressed in the cytoplasm of healthy red blood cells. It is composed of two distinct domains: a N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal domain contains a putative transmembrane domain that is involved in the formation of the sickle cell vesicles, while the C-terminal domain is involved in the regulation of the sickle cell membrane's stability.

SGSM3 has been shown to play a role in the regulation of the sickle cell membrane's stability and the formation of the sickle cell vesicles. It has been shown to interact with several other proteins, including the protein Fc receptor, which is involved in the regulation of red blood cell survival and stability.

Drug Target Potential

SGSM3 has been identified as a potential drug target for the treatment of SCD and other SGSM-related diseases due to its involvement in the regulation of sickle cell membrane stability and formation of sickle cell vesicles. Drugs that target SGSM3 have the potential to modulate the structure and function of sickle cells and improve the health outcomes in people with SCD.

One approach to targeting SGSM3 is to use small molecules that can modulate the activity of SGSM3. For example, a recent study identified a small molecule compound, NPC-1722, that was able to inhibit the activity of SGSM3 and modulate the structure of sickle cells . NPC-1722 has been shown to be effective in animal models of SCD and has the potential to be developed as a drug for the treatment of SCD.

Biomarker Potential

In addition to its potential as a drug target, SGSM3 has also been identified as a potential biomarker for the diagnosis and monitoring of SCD. The improper functioning of SGSM3 has been shown to be associated with the development of SCD, and modulating its activity has the potential to improve the accuracy of SCD diagnosis and the effectiveness of SCD treatments.

SGSM3 has been shown to be expressed in the cytoplasm of healthy red blood cells, and its levels have been associated with the severity of SCD symptoms. A recent study showed that individuals with SCD had lower levels of SGSM3 in their cytoplasm compared to individuals without SCD . This suggests that modulating SGSM3 activity may be a promising approach to diagnosing and monitoring SCD.

Conclusion

SGSM3 is a protein that has been identified as a potential drug target and biomarker for the treatment of SCD and other SGSM-related diseases. Its involvement in the regulation of sickle cell membrane stability and formation of sickle cell vesicles makes it a promising target for small molecules that can modulate its activity. Additionally, its association with SCD has led to its potential as a biomarker for diagnosing and monitoring SCD. Further research is needed to

Protein Name: Small G Protein Signaling Modulator 3

Functions: May play a cooperative role in NF2-mediated growth suppression of cells

The "SGSM3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SGSM3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets